Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IACS-010759 in Advanced Solid Tumors and Lymphoma
NCT03291938Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IACS-010759 in solid tumor and lymphoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of adverse events up to 2 years and Maximum tolerated dose. Started Nov 2017; status: completed.
02
Drugs
IACS-010759
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03291938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03291938.